Fundraising Fox
Nagibio
Not stated, CH · Founded 2019 · 58 employees on LinkedIn · 3 known investors
Find your way into Nagibio
Sign up to see every warm intro you have to Nagibio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nagibio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nagi Bioscience provides in vivo toxicity testing services using organism-on-chip technology with C. elegans models, serving pharmaceutical, chemical, and biotech companies seeking faster, ethical alternatives to traditional animal testing. The company delivers high-throughput developmental, reproductive, and eco-toxicity assays aligned with regulatory frameworks.
Founders & leadership
Nagibio was founded in 2019 by Dr. Matteo Cornaglia and Dr. Laurent Mouchiroud.
Investors · 3
How we know: Excellis Holding's portfolio page · Not right? Tell us
How we know: imec.xpand's portfolio page · the VCSheet dataset · Not right? Tell us
.jpeg){kind=logo}
Frequently asked questions
- What does Nagibio do?
- Nagi Bioscience provides in vivo toxicity testing services using organism-on-chip technology with C. elegans models, serving pharmaceutical, chemical, and biotech companies seeking faster, ethical alternatives to traditional animal testing. The company delivers high-throughput developmental, reproductive, and eco-toxicity assays aligned with regulatory frameworks.
- Who founded Nagibio?
- Nagibio was founded by Dr. Matteo Cornaglia, Dr. Laurent Mouchiroud in 2019.
- Who are Nagibio's investors?
- Nagibio's investors include Excellis Holding, imec.xpand, Verve Ventures.
- Where is Nagibio headquartered?
- Nagibio is headquartered in Not stated, CH.